Rapport Therapeutics Common Stock

Rapport Therapeutics posts a common stock of $48K as of June 2026. That compares with $37K in the prior-year period — up 29.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Rapport Therapeutics's common stock was $37K. The latest reading is $48K — a 29.7% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Common Stock is one piece of Rapport Therapeutics's financial statement story. At $48K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for RAPP's common stock usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Rapport Therapeutics's other metric pages and overview cover the third.